Cargando…

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement

Programmed death-ligand 1 (PD-L1) expression is a predictor of immune checkpoint inhibitor (ICI) treatment efficacy. The clinical efficacy of ICIs for non-small-cell lung cancer (NSCLC) patients harboring major mutations, such as EGFR or ALK mutations, is limited. We genotyped 190 patients with adva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oya, Yuko, Kuroda, Hiroaki, Nakada, Takeo, Takahashi, Yusuke, Sakakura, Noriaki, Hida, Toyoaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178012/ https://www.ncbi.nlm.nih.gov/pubmed/32283823 http://dx.doi.org/10.3390/ijms21072623

Ejemplares similares

Survival benefit of immune checkpoint inhibitor monotherapy in patients with non-small cell lung cancer recurrence after completely pulmonary resection
por: Kuroda, Hiroaki, et al.
Publicado: (2021)

Clinical adjustability of radiological tools in patients with surgically resected cT1N0-staged non-small-cell lung cancer from the long-term survival evaluation
por: Kuroda, Hiroaki, et al.
Publicado: (2020)

Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with ALK rearrangement
por: Seto, Katsutoshi, et al.
Publicado: (2018)

Clinical Guideline-Guided Outcome Consistency for Surgically Resected Stage III Non-Small Cell Lung Cancer: A Retrospective Study
por: Kuroda, Hiroaki, et al.
Publicado: (2021)

Sarcopenia is poor risk for unfavorable short- and long-term outcomes in stage I non-small cell lung cancer
por: Takahashi, Yusuke, et al.
Publicado: (2021)

An extended modification of transmanubrial osteomuscular sparing approach: salvage resection for recurrent superior sulcus lung cancer after definitive chemoradiotherapy
por: Sakakura, Noriaki, et al.
Publicado: (2021)

Subsegmental resection preserves regional pulmonary function: A focus on thoracoscopy
por: Kuroda, Hiroaki, et al.
Publicado: (2021)

Serum ProGRP and NSE levels predicting small cell lung cancer transformation in a patient with ALK rearrangement-positive non-small cell lung cancer: A case report
por: Oya, Yuko, et al.
Publicado: (2018)

Resection of an anterior apical tumor invading the ventral first rib: a less invasive lateral thoracotomy approach
por: Sakakura, Noriaki, et al.
Publicado: (2022)

Importance of avoiding surgery delays after initial discovery of suspected non-small-cell lung cancer in clinical stage IA patients
por: Kuroda, Hiroaki, et al.
Publicado: (2018)

Prognostic Radiological Tools for Clinical Stage IA Pure Solid Lung Cancer
por: Nakada, Takeo, et al.
Publicado: (2021)

Three-Arm Robotic Lung Resection via the Open-Thoracotomy-View Approach Using Vertical Port Placement and Confronting Monitor Setting: Focusing on Segmentectomy
por: Sakakura, Noriaki, et al.
Publicado: (2022)

Life-threatening massive bleeding in the pulmonary trunk adjacent to the right ventricular outflow tract during the resection of a large mediastinal germ cell tumor: proposed safety measures in the absence of cardiovascular surgeons: a case report
por: Sakakura, Noriaki, et al.
Publicado: (2021)

Risk factors for postoperative nausea and vomiting after thoracoscopic pulmonary wedge resection: pitfalls of an increased fentanyl dose
por: Nakai, Aiko, et al.
Publicado: (2021)

Emergency rollout and conversion procedures during the three-arm robotic open-thoracotomy-view approach
por: Sakakura, Noriaki, et al.
Publicado: (2021)

Novel strategy to treat lung metastases: Hybrid therapy involving surgery and radiofrequency ablation
por: Hasegawa, Takaaki, et al.
Publicado: (2021)

Thoracoscopic lobectomy using indocyanine green fluorescence to detect the interlobar fissure in a patient with displaced B3 and absence of fissure: A case report
por: Nakanishi, Keita, et al.
Publicado: (2019)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
por: Oya, Yuko, et al.
Publicado: (2017)

Permissible Outcomes of Lobe-Specific Lymph Node Dissection for Elevated Carcinoembryonic Antigen in Non-Small Cell Lung Cancer
por: Kuroda, Hiroaki, et al.
Publicado: (2021)

Successful salvage surgery following multimodal therapy in a patient who harboured ALK‐rearranged advanced lung adenocarcinoma with multiple organ metastases
por: Horio, Yoshitsugu, et al.
Publicado: (2019)

Correction to: Divided method of intercostal nerve block reduces ropivacaine dose by half in thoracoscopic pulmonary resection while maintaining the postoperative pain score and 4-h mobilization: a retrospective study
por: Nakai, Aiko, et al.
Publicado: (2023)

Divided method of intercostal nerve block reduces ropivacaine dose by half in thoracoscopic pulmonary resection while maintaining the postoperative pain score and 4-h mobilization: a retrospective study
por: Nakai, Aiko, et al.
Publicado: (2023)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
por: Cao, Shuhui, et al.
Publicado: (2022)

Combined immune checkpoint inhibitor and chemotherapy is effective in a patient with ALK rearranged non-small cell lung cancer: a case report
por: Xia, Lexin, et al.
Publicado: (2020)

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
por: Papageorgiou, Savvas, et al.
Publicado: (2022)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Oulhen, Marianne, et al.
Publicado: (2021)

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib
por: Nishino, Mizuki, et al.
Publicado: (2020)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

The cranial-side parietal pleura pick-up method and the edge closure technique as a closure method for open thoracotomy
por: Sakakura, Noriaki, et al.
Publicado: (2020)

Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report
por: Hu, Han, et al.
Publicado: (2022)

ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis
por: Jiang, Jun, et al.
Publicado: (2022)

Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer
por: Sakashita, Takuya, et al.
Publicado: (2022)

A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report
por: Kashima, Jumpei, et al.
Publicado: (2016)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer
por: Motoo, Iori, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kfos3h9b2v6sfoi1bp4qo11a9b